— Total revenue of $2.8 billion, up 15% over Q3 2024 — AtkinsRéalis Services revenue(1) and Segment Adjusted EBIT(1) both up 17% — Diluted EPS from PS&PM of $0.84, up 68%, and Adjusted diluted EPS from PS&PM(2) of $1.06, up 68% over Q3 2024 — Net cash generated from operating activities of $123 million — […]
MolecuLight Corp., a global leader in point-of-care fluorescence imaging for wound assessment, is proud to announce the publication of a landmark international consensus report, developed by leading experts in wound care and surgery from across the United States. The report, titled “Fluorescence imaging in surgical wound management: A consensus-based approach”, represents a pivotal step toward
Ottawa, Nov. 13, 2025 (GLOBE NEWSWIRE) — The global mRNA synthesis & manufacturing market size is calculated at USD 1.55 billion in 2024, grows to USD 1.58 billion in 2025, and is projected to hit around USD 1.87 billion by 2034, growing at a CAGR of 1.9% from 2025 to 2034. mRNA Synthesis & Manufacturing
mRNA Synthesis & Manufacturing Market Size to Hit USD 1.87 Billion by 2034 According to Nova One Advisor, the global mRNA synthesis & manufacturing market size is calculated at USD 1.58 billion in 2025 and is expected to be hit around USD 1.87 billion by 2034, growing at a compound annual growth rate (CAGR) of
Golia Dental, a trusted name in Hamden's dental care community for decades, has officially rebranded as Hamden Dental Arts under the leadership of Dr. Nishan Halim. The change honors the longstanding legacy of founder Dr. Robert Golia while ushering in a new era of modern, technology-driven dentistry. https://mma.prnewswire.com/media/2808434/Hamden_Dental_Arts_Logo.jpg Dr. Robert Golia, who cared for Hamden
Appcast Chief Product Officer Matt Plummer will provide a sneak peek into the findings of Appcast's upcoming whitepaper, “Top Recruiting Trends of 2026” What: Appcast, the leading recruitment marketing platform powered by programmatic, will hold a live webinar hosted by Appcast Chief Product Officer Matt Plummer. He will provide an inside look at the recruiting
(NYSE MKT:SER), HUNTSVILLE, Nov. 13, 2025 (GLOBE NEWSWIRE) — Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead Investigational New Drug (“IND”) candidate, SER-252, for advanced Parkinson's disease, enabled by its proprietary POZ Platform(TM) drug optimization technology, today announced its financial results for the third quarter ended
Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights GlobeNewswire November 13, 2025 HUNTSVILLE, Nov. 13, 2025 (GLOBE NEWSWIRE) — Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead Investigational New Drug (“IND”) candidate, SER-252, for advanced Parkinson's disease, enabled by its proprietary POZ
HAPPE Spine, an early stage company advancing clinical outcomes with a proprietary biomaterial and manufacturing platform for creating bone-integrating implants, announces that the INTEGRATE®-C Interbody Fusion System has been implanted in more than 1,000 patients, demonstrating clinical adoption of the HAPPE® platform across more than 30 surgeon users and 40 facilities nationwide. https://mma.prnewswire.com/media/2821692/HAPPE_Spine_Logo.jpg The INTEGRATE®-C
DUBAI, United Arab Emirates, Nov. 13, 2025 (GLOBE NEWSWIRE) — The crypto market continues to evolve rapidly, with investors paying close attention to new DeFi projects showing early signs of strong adoption. Among the emerging names, Mutuum Finance (MUTM) has quickly become one of the top cryptos on investor watchlists. The project's ecosystem has seen